Skip to main content
SpringerLink
Log in

Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Intravenous elotuzumab (Empliciti™), a monoclonal antibody targeting the signalling lymphocytic activation molecule F7 (SLAMF7) glycoprotein, is approved for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in previously-treated adult patients. In the pivotal, multinational, phase III ELOQUENT-2 trial in adults with relapsed and/or refractory multiple myeloma, elotuzumab in combination with lenalidomide and dexamethasone significantly prolonged median progression-free survival (PFS) and increased overall response rate (ORR; co-primary endpoints) compared with lenalidomide and dexamethasone alone. The clinical benefit of elotuzumab was maintained over the longer term (≤ 4 years’ minimum follow-up); final overall survival data are awaited. Health-related quality of life was not negatively impacted by the addition of elotuzumab. Elotuzumab combination therapy had a generally manageable tolerability profile and the most common adverse events (AEs) of grade ≥ 3 severity were haematological (e.g. lymphocytopenia, anaemia, thrombocytopenia, neutropenia). Elotuzumab plus lenalidomide and dexamethasone extends the treatment options available for the management of relapsed and/or refractory multiple myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol. 2016;9:52.

    Article  Google Scholar 

  2. Lonial S, Durie B, Palumbo A, et al. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30:526–35.

    Article  CAS  Google Scholar 

  3. Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–37.

    Article  CAS  Google Scholar 

  4. Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–85.

    Article  CAS  Google Scholar 

  5. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–31.

    Article  CAS  Google Scholar 

  6. Bristol-Myers Squibb Pharma EEIG. Empliciti: summary of product characteristics. 2017. http://www.ema.europa.eu/. Accessed 9 Aug 2018.

  7. Bristol-Myers Squibb Company. Empliciti™ (elotuzumab) for injection, for intravenous use: US prescribing information. 2017. http://packageinserts.bms.com/. Accessed 9 Aug 2018.

  8. Bristol-Myers Squibb. Humanized anti-human SLAMF 7 monoclonal antibody. Empliciti® for IV infusion: Japanese prescribing information. 2016. http://www.pmda.go.jp/. Accessed 9 Aug 2018.

  9. Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841–9.

    Article  CAS  Google Scholar 

  10. Kurdi AT, Glavey SV, Bezman NA, et al. Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab. Mol Cancer Ther. 2018;17(7):1454–63.

    Article  CAS  Google Scholar 

  11. Rice AG, Dillon MBC, Van Abbema AM, et al. HuLuc63 in combination regimens with conventional and targeted therapies has additive and synergistic anti-tumour activity in pre-clinical models of myeloma. Blood. 2007;110(11):2517.

    Google Scholar 

  12. Balasa B, Yun R, Belmar NA, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways. Cancer Immunol Immunother. 2015;64(1):61–73.

    Article  CAS  Google Scholar 

  13. Van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616–24.

    Article  Google Scholar 

  14. Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896–905.

    Article  CAS  Google Scholar 

  15. Richardson PG, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12):e516–27.

    Article  Google Scholar 

  16. Gibiansky L, Passey C, Roy A, et al. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma. J Pharmacokinet Pharmacodyn. 2016;43(3):243–57.

    Article  CAS  Google Scholar 

  17. Passey C, Mora J, Dodge R, et al. An integrated assessment of the effects of immunogenicity on the pharmacokinetics, safety, and efficacy of elotuzumab. AAPS J. 2017;19(2):557–67.

    Article  CAS  Google Scholar 

  18. European Medicines Agency. Empliciti: CHMP assessment report. 2016. http://www.ema.europa.eu/. Accessed 9 Aug 2018.

  19. Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin Lymphoma Myeloma Leuk. 2016;16(3):129–38.

    Article  Google Scholar 

  20. Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018. https://doi.org/10.1002/cncr.31680.

    Article  PubMed  Google Scholar 

  21. Suzuki K, Sunami K, Ohashi K, et al. Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis. Blood Cancer J. 2017;7(3):e540.

    Article  CAS  Google Scholar 

  22. Cella D, McKendrick J, Kudlac A, et al. Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. Ann Hematol. 2018. https://doi.org/10.1007/s00277-018-3469-4.

    Article  PubMed  PubMed Central  Google Scholar 

  23. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma (version 4.2018). 2018. http://www.nccn.org/. Accessed 9 Aug 2018.

  24. Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;24(Suppl 6):vi133–7.

    Google Scholar 

  25. Ailawadhi S, DerSarkissian M, Duh MS, et al. Cost offsets in the treatment journeys of patients with relapsed/refractory multiple myeloma (RRMM) [abstract no. 5599]. Blood. 2017;130(Suppl 1):5599.

    Google Scholar 

Download references

Acknowledgements

During the peer review process, the manufacturer of elotuzumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Yvette N. Lamb

Authors
  1. Yvette N. Lamb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yvette N. Lamb.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Yvette Lamb is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: N. Callander University of Wisconsin Carbone Cancer Center, Madison, WI, USA; C. Cerchione Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lamb, Y.N. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma. Drugs 78, 1481–1488 (2018). https://doi.org/10.1007/s40265-018-0969-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-018-0969-4

Search

Navigation